Tuxobertinib
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 19, 2019 (NCT04209465)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
EGFR inhibitor
- Epidermal growth factor receptor erbB1NEGATIVE ALLOSTERIC MODULATOR
Epidermal growth factor receptor erbB1 negative allosteric modulator
Allosteric, irreversible, ATP competitive inhibitor
Selective for mutants vs. wild-type.
- Receptor protein-tyrosine kinase erbB-2NEGATIVE ALLOSTERIC MODULATOR
Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator
Allosteric, irreversible, ATP competitive inhibitor
Selective for mutants vs. wild-type.
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1OCCN1CCOCC1- Mol. weight
- 561.04 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650279 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04209465 | Phase 1/Phase 2 (Phase 2) | Dec 19, 2019 | Black Diamond Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1